You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

BAVENCIO Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for BAVENCIO

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Erasmus Medical CenterPhase 2
NRG OncologyPhase 2
Bradley A. McGregorPhase 2

See all BAVENCIO clinical trials

Recent Litigation for BAVENCIO

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.2022-03-17

See all BAVENCIO litigation

Pharmacology for BAVENCIO
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BAVENCIO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BAVENCIO Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for BAVENCIO Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for the Biologic Drug: BAVENCIO

Introduction

BAVENCIO (avelumab), an anti-programmed death ligand-1 (PD-L1) monoclonal antibody, has been a significant player in the oncology market since its introduction. Developed by Merck KGaA and initially co-developed and co-commercialized with Pfizer, BAVENCIO has navigated a complex market landscape marked by intense competition and evolving treatment paradigms.

Regulatory Approvals and Indications

BAVENCIO has received several key regulatory approvals that define its market presence. It is authorized for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy. Additionally, it is indicated in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC) and as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC)[5].

Market Competition

The immune checkpoint inhibitor (ICI) market is highly competitive, with BAVENCIO facing stiff competition from other PD-L1 and PD-1 inhibitors. In the bladder cancer space, for instance, BAVENCIO competes with combinations like Keytruda and Padcev, which have recently entered the market and pose a significant threat to BAVENCIO’s market share[1].

Bladder Cancer Market

Despite the success of the Phase III JAVELIN Bladder 100 study, BAVENCIO’s impact in the bladder cancer market is limited by the presence of other strong contenders. The combination of Keytruda with Padcev has been particularly challenging, as it has gained significant traction in the first-line bladder cancer treatment landscape[1][3].

Renal Cell Carcinoma (RCC)

In the RCC space, BAVENCIO in combination with Inlyta showed a favorable trend but missed the survival mark compared to Pfizer's Sutent. This outcome highlights the competitive nature of the RCC market and the challenges BAVENCIO faces in establishing a strong foothold[1].

Financial Performance

Sales and Revenue Growth

BAVENCIO has shown steady revenue growth despite the competitive landscape. In the first quarter of 2024, BAVENCIO’s sales increased by 14% year over year at constant exchange rates to 186 million euros. This growth is significant, especially considering that only about 30% of BAVENCIO’s sales come from the U.S. market[1].

Projections and Expectations

Merck KGaA anticipates continued growth for BAVENCIO, driven by its solid organic growth and the ramp-up of other key drugs like Mavenclad. The company expects the Healthcare division to achieve 8%-9% organic growth in 2021, largely due to mid-double-digit sales growth for Mavenclad and BAVENCIO[2].

Strategic Developments

Exclusive Rights and Partnership Changes

In a significant strategic move, Merck KGaA regained exclusive worldwide rights to develop, manufacture, and commercialize BAVENCIO from Pfizer, effective June 30, 2023. This change includes a 15% royalty to Pfizer on net sales of BAVENCIO. Merck will now control all future research and development activities, ensuring continuous and reliable access to the drug for patients[5].

Clinical Trials and Pipeline

Merck and Pfizer will continue to operationalize their respective ongoing clinical trials for BAVENCIO. Merck’s focus on late-stage pipeline development and its broader oncology portfolio positions BAVENCIO for continued relevance in the market. However, the drug’s future success may depend on its performance in niche areas such as glioblastomas, cancers with brain metastasis, and rare forms of blood cancers, where combinations with novel checkpoint modulators could provide a competitive edge[3][5].

Challenges and Opportunities

Competitive Pressure

BAVENCIO faces intense competition from other ICIs, particularly in the lung cancer segment where it competes with drugs like AstraZeneca’s Tagrisso. The failure to secure a first-line indication in lung cancer could cap BAVENCIO’s sales potential at around $500 million annually[2].

Niche Indications

Despite previous disappointments in treating certain malignancies with ICIs alone, BAVENCIO still has untapped potential in niche areas. Combinations with other immunotherapies might offer the necessary edge to seize opportunities in indications like T-cell lymphoma and prostate cancer[3].

Financial Projections and Guidance

Revenue Growth and Margins

Merck KGaA expects solid organic growth for its top-10 drugs, including BAVENCIO, which will help offset declines from other products. The company anticipates revenue growth of about 5% in 2020 and up to 6.5% in 2021, with the Healthcare division achieving 8%-9% organic growth due to the successful ramp-up of BAVENCIO and Mavenclad[2].

Cost Management and Synergies

The company’s financial performance will also be influenced by cost management and synergies from recent acquisitions. The adjusted EBITDA margin is expected to increase slightly, supported by decreasing SG&A costs and the extraction of synergies following the Versum Materials acquisition[2].

Key Takeaways

  • Regulatory Approvals: BAVENCIO is approved for several key oncology indications, including urothelial carcinoma, renal cell carcinoma, and Merkel cell carcinoma.
  • Market Competition: BAVENCIO faces significant competition in the ICI market, particularly from combinations like Keytruda and Padcev.
  • Financial Performance: BAVENCIO has shown steady revenue growth, with a 14% year-over-year increase in the first quarter of 2024.
  • Strategic Developments: Merck KGaA has regained exclusive worldwide rights to BAVENCIO, with a focus on late-stage pipeline development and niche indications.
  • Challenges and Opportunities: BAVENCIO’s future success depends on its performance in competitive markets and its potential in niche areas.

FAQs

What are the approved indications for BAVENCIO?

BAVENCIO is approved for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma, in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma, and as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma[5].

How does BAVENCIO perform in the competitive ICI market?

BAVENCIO faces intense competition from other ICIs, particularly in the bladder cancer and lung cancer segments. Despite this, it has shown steady revenue growth and remains a significant player in the oncology market[1][2].

What is the impact of Merck KGaA regaining exclusive rights to BAVENCIO?

Merck KGaA’s decision to regain exclusive worldwide rights to BAVENCIO allows the company to control all future research and development activities, ensuring continuous and reliable access to the drug for patients. This move is part of Merck’s focused leadership strategy in oncology[5].

What are the potential niche areas for BAVENCIO?

BAVENCIO has potential in niche areas such as glioblastomas, cancers with brain metastasis, and rare forms of blood cancers like T-cell lymphoma. Combinations with novel checkpoint modulators could provide the necessary edge for success in these indications[3].

How does BAVENCIO’s financial performance align with Merck KGaA’s overall financial projections?

BAVENCIO’s revenue growth contributes to Merck KGaA’s overall financial performance, with the company expecting solid organic growth and increased margins due to the successful ramp-up of BAVENCIO and other key drugs[2].

Sources

  1. FiercePharma: ASCO: Merck KGaA's Bavencio combo misses survival mark in RCC[1]
  2. Merck Group: Standard & Poor's Rating Report[2]
  3. Clinical Trials Arena: Future of Merck KGaA/Pfizer's Bavencio at risk despite bladder trial success[3]
  4. Pfizer: Q4 2023 Earnings Release[4]
  5. Merck Group: Oncology - BAVENCIO (avelumab)[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.